NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Grant supports planning & implementing clinical trials in dental research through UG3/UH3 cooperative agreement applications with NIDCR.
Funder: National Institutes of Health
Due Dates: May 8, 2025 (AIDS) | June 6, 2025 (New) | July 7, 2025 (Renewal/Resubmission/Revision) | September 4, 2025 (AIDS) | October 7, 2025 (New) | November 6, 2025 (Renewal/Resubmission/Revision) | January 6, 2026 (AIDS) | and additional dates through January 2028
Funding Amounts: UG3 phase: <$400,000 direct costs (1 year); UH3 phase: no set limit, up to 5 years; total project period up to 6 years. Budgets over $500,000/year require pre-approval.
Summary: Supports planning and implementation of clinical trials for drugs, biologics, devices, or procedures addressing dental, oral, or craniofacial conditions through a phased UG3/UH3 cooperative agreement with NIDCR.
Key Information: Only applications proposing clinical trials are accepted; initial UG3 funding does not guarantee UH3 support; limited submission—see eligibility details.
Description
This opportunity from the National Institute of Dental and Craniofacial Research (NIDCR) supports investigator-initiated clinical trials aimed at improving dental, oral, or craniofacial health. The mechanism is a phased cooperative agreement (UG3/UH3), with an initial one-year planning phase (UG3) and, contingent on meeting milestones, a subsequent implementation phase (UH3) of up to five years. The program is designed for trials testing drugs, biologics, devices, or procedures, including any phase of FDA-regulated products, but does not support behavioral intervention trials.
The NIDCR will be substantially involved in the scientific and operational aspects of funded projects, providing guidance and oversight throughout both phases.
